Physician profile
Caroline Mann
NPI 1013934579
$1,974.08
in general payments reported to CMS, 2019-2025
19 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $77.03 · 2022: $30.30 · 2023: $511 · 2024: $947 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.02 |
| Education | $228.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $372.34 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $256.97 | 2019-2025 | |
| Galderma Laboratories, L.P. | $231.11 | 2022-2024 | Aklief, Oracea, Epsolay |
| Ucb, INC. | $204.97 | 2024 | Bimzelx |
| Lilly USA, LLC | $179.16 | 2024-2025 | Olumiant, Taltz, Zepbound |
| Pfizer INC. | $118.81 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $90.30 | 2023-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $79.34 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $79.34 | 2023-2024 | |
| Allergan, INC. | $77.03 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.91 | 2023 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $57.60 | 2024 | Zoryve |
| Biofrontera INC. | $38.65 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Janssen Biotech, INC. | $33.21 | 2024-2025 | Tremfya |
| Janssen Pharmaceuticals, INC | $33.10 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25.10 | 2024 | Sotyktu |
| Paratek Pharmaceuticals, INC. | $16.26 | 2023 | Nuzyra |
| Genzyme Corporation | $14.27 | 2024 | |
| Organon LLC | $7.61 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.